MetaVia ends DA-1726 Part 3A visits; data due Q1 2027
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MetaVia Inc. (MTVA) said the last patient completed the final visit in Part 3A of its Phase 1 DA-1726 trial. The company extended treatment from 16 to 24 weeks at 48 mg weekly, citing encouraging preliminary safety and tolerability observations. Full Part 3A and 3B data are expected in the first quarter of 2027.
Previously reported Part 3B interim results showed a statistically significant 68.1% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss. All five treated participants with liver steatosis at baseline had MRI-PDFF below 5% by Day 109. MetaVia targets a Phase 2, 48-week, non-biopsy study in up to 150 patients with MetALD and ALD for the second half of 2027.
8-K Event Classification
Key Figures
Key Terms
GLP-1 (GLP1R)/glucagon (GCGR) dual-receptor agonist medical
MRI-PDFF medical
placebo-adjusted medical
MetALD medical
ALD medical
HbA1c medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were MTVA's interim DA-1726 Part 3B results?
When does MTVA plan to start Phase 2 testing of DA-1726?
AI-generated analysis. How Rhea-AI works. Not financial advice.

